2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Glen J Pearson, George Thanassoulis, Todd J Anderson...
https://pubmed.ncbi.nlm.nih.gov/33781847/Actively Recruiting
Led by University of Alberta · Updated on 2026-09-09
2000
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating whether a proactive approach guided by electronic health records EHR helps more people reach safe cholesterol levels after a heart event, such as a heart attack. The study aims to see if this method improves medication use and lowers the risk of future heart attacks and strokes compared to usual care. The main goal is to determine if this approach increases the number of patients who reach the LDL-cholesterol target of less than 1.8 mmolL at six months. Participants in the intervention group receive monthly contact from a pharmacist who can order repeat blood tests, review medications, check adherence and side effects, and adjust treatment based on national dyslipidemia guidelines. This active support continues until patients reach their cholesterol targets or choose to stop participating. The control group receives usual care, which includes follow-up with their primary cardiologist, primary care doctor, cardiac rehabilitation team, and community pharmacy, following standard Canadian care guidelines. During the study, researchers collect data on demographics, medical history, laboratory values, medication use, and clinical outcomes from health records. They measure cholesterol levels and treatment changes at three and six months, and track major events such as death, heart attacks, strokes, and coronary procedures up to five years. Participants involvement in the intervention can last up to six months, and the study continues monitoring outcomes for up to five years in total.
CONDITIONS
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
C
Canadian VIGOUR Centre
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Alberta
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 6 months
Participants either receive monthly pharmacist support including medication reviews and treatment adjustments, or continue with usual care following standard guidelines.
Monthly contact for intervention group; usual care as scheduled
Duration - Up to 5 years
Researchers monitor cholesterol levels and clinical outcomes such as heart attacks and strokes for up to five years after enrollment.
Periodic data collection from health records
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Glen J Pearson, George Thanassoulis, Todd J Anderson...
https://pubmed.ncbi.nlm.nih.gov/33781847/Bimmer E Claessen, Paul Guedeney, C Michael Gibson...
https://pubmed.ncbi.nlm.nih.gov/33289416/Pishoy Gouda, Anamaria Savu, Kevin R Bainey...
https://pubmed.ncbi.nlm.nih.gov/34197547/Robert C Welsh, Pishoy Gouda, Doug Dover...
https://pubmed.ncbi.nlm.nih.gov/38582637/University of Alberta
Lead Sponsor